Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAMP3 | O60896 | 1/20 | 0.60 |
| ▸ | CALCR | P30988 | 1/20 | 0.60 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.59 |
| ▸ | NPY2R | P49146 | 6/20 | 0.58 |
| ▸ | NPY4R | P50391 | 6/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.58 |
| ▸ | NPY1R | P25929 | 4/20 | 0.58 |
| ▸ | TFPI | P10646 | 2/20 | 0.58 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.58 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.58 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29521469 | 0.93 | NPY2R (0.61) | OPRD1NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30363258 | 0.93 | RAMP3 (0.59) | RAMP3CALCROPRD1NPY2RNPY4R | |
| SCHEMBL31519870 | 0.88 | OPRD1 (0.66) | OPRD1NTSR1 | |
| SCHEMBL31519869 | 0.88 | OPRD1 (0.64) | OPRD1NTSR1 | |
| SCHEMBL30888269 | 0.87 | NPY2R (0.70) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31519873 | 0.87 | OPRD1 (0.62) | OPRD1NPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL31519871 | 0.86 | OPRD1 (0.66) | OPRD1NTSR1 | |
| SCHEMBL31020752 | 0.86 | NPY2R (0.64) | CALCRNPY2RNPY4RNPY5RNPY1R | |
| SCHEMBL30906464 | 0.86 | NPY2R (0.70) | RAMP3CALCRNPY2RNPY4RNPY5R | |
| SCHEMBL29649229 | 0.86 | NPY2R (0.67) | RAMP3CALCRNPY2RNPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12171836-B2 | Long-acting adrenomedullin derivative | UNIVERSITY OF MIYAZAKI (JP) | 2024-12-24 | — | — | US | disclosed |
| US-20230142095-A1 | Long-Acting Adrenomedullin Derivative | UNIVERSITY OF MIYAZAKI (JP) | 2023-05-11 | — | — | US | disclosed |
| US-11478551-B2 | Long-acting adrenomedullin derivative | UNIVERSITY OF MIYAZAKI (JP) | 2022-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12171836-B2 | Long-acting adrenomedullin derivative | CRH, NPPA, VIP | RAMP3 535/4885CALCR 160/4885OPRD1 368/4885 |
| US-20230142095-A1 | Long-Acting Adrenomedullin Derivative | CRH, NPPA, VIP | RAMP3 535/4885CALCR 160/4885OPRD1 368/4885 |
| US-11478551-B2 | Long-acting adrenomedullin derivative | CRH, NPPA, AVPR1B | RAMP3 544/4885CALCR 152/4885OPRD1 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.